


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MARK B. WILSON
PARTNER
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

January 14, 2003

| | |
|---|---|
| CERTIFICATE OF FACSIMILE TRANSMISSION 37 C.F.R. § 1.8 | |
| I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, Washington, D.C. 20231, c/o Examiner Mary Mosher, facsimile number (703) 746-5258 on the date below: | |
| January 14, 2003 Date |  Mark B. Wilson |

VIA FACSIMILE (703) 746-5258

Commissioner for Patents
Washington, D.C. 20231

Re: SN 09/993,363 "INDUCTION OF IMMUNITY USING INHIBITORS OF
GRANZYMES" by Philip G. Ashton-Rickardt and Joseph T. Opferman -
Client Ref. UCHI:917
Our Ref. ARCD:382US/10109293

Commissioner:

Enclosed for filing in the above-referenced patent application is a Substitute Response to Restriction Requirement and Species Election Requirement dated November 12, 2002.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/ARCD:382US.

Very truly yours,



Mark B. Wilson
Reg. No. 37,259

MBW/vv
Enclosure

25251475.1

AUSTIN • DALLAS • HONG KONG • HOUSTON • LONDON • LOS ANGELES • MINNEAPOLIS • MUNICH • NEW YORK • SAN ANTONIO • WASHINGTON DC

Received from <512 536 4598> at 1/14/03 2:58:08 PM [Eastern Standard Time]

VIA FACSIMILE: 703-746-5258
ATTN: EXAMINER MARY MOSHER

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Philip G. Ashton-Rickardt
Joseph T. Opferman

Group Art Unit: 1648

Examiner: Mary Mosher

Serial No.: 09/993,363

Atty. Dkt. No.: ARCD:382US/MBW

Filed: November 14, 2001

For: INDUCTION OF IMMUNITY USING
INHIBITORS OF GRANZYMES

CERTIFICATE OF FACSIMILE TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being
transmitted to: Commissioner for Patents, Washington,
D.C. 20231, c/o Examiner Mary Mosher, facsimile number
(703) 746-5258 on the date below:

January 14, 2003
Date,


Mark B. Wilson

**SUBSTITUTE RESPONSE TO RESTRICTION REQUIREMENT AND SPECIES
ELECTION REQUIREMENT DATED NOVEMBER 12, 2002**

Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is submitted as a Substitute Response to the Response Restriction Requirement and Species Election Requirement filed in this case on December 12, 2002.

No fees are believed due with this response. However, should any fee under 37 C.F.R. §§ 1.16 to 1.21 be deemed required for any reason pertaining to this paper, consider this paragraph a request and authorization to withdraw the appropriate fee from Fulbright & Jaworski Deposit Account No. 50-1212/ARCD:382US.

A. Restriction Requirement

In response to the Restriction Requirement imposed by the Examiner, Applicants had elected, without traverse, to prosecute claims 1-25, *i.e.*, the Group I claims, in a Response filed on December 12, 2002. However, as discussed with the Examiner, in view of the clients commercial interests Applicants now elect the Group II set of claims. The Group II invention encompasses claims 26-50 which are directed to therapeutic methods for enhancing or inducing immunity comprising administering to a subject in need thereof compositions comprising expression constructs encoding granzyme inhibitors.

B. Species Election Requirement

The Examiner has also entered a Species Election Requirement and subdivided all the Groups I, II and III inventions as containing claims to "species of disease treated" and identified the following diseases: HIV, LCMV, HCV, HTLV-1, HTLV-2, EBV, HBV, HCMV, HSV-1, HSV-2, HGV, enterovirus, dengue, rabies, melanoma, colon cancer, prostate cancer, renal cancer, non-Hodgkin lymphoma, sarcoma, B-cell leukemia, lung cancer and breast cancer. In this regard, Applicants currently elect HIV, as a species for initial examination. Current claims 20-43 and 48-50 encompass the elected species. If any generic claim, such as any of current claims 26-42, and 48-50 is found allowable, Applicants reserve the right to reintroduce claims to the remaining species in the present case.


The Examiner has also entered another Species Election Requirement and required the election of a single species of inhibitor and listed the following species: antibody, small molecule, PI9 mimetic, SPI6, PI9, PI-6, MNEI, PI-8, and PAI-2. In this regard, Applicants

currently elect PI9, as a species for initial examination. Claims 26-38 and 40-50 currently encompass this species. However, if any generic claim, such as any of current claims 26-38 and 41-50 is found allowable, Applicants reserve the right to reintroduce claims to the remaining species in the present case.

C. Conclusion

Applicants respectfully request favorable consideration of this case in view of the above. Should the Examiner have any questions, comments, or suggestions relating to this case, the Examiner is invited to contact the undersigned Applicants' representative at (512)-536-3035.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512-536-3035
Date: January 14, 2003